R&D News | pharmaphorum

News

Colourised transmission electron micrograph of mpox virus particles

NIH study backs Bavarian Nordic mpox jab for adolescents

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in the US – is also safe and generates a strong antibody response in

News

Wave Life Sciences president and CEO Paul Bolno

Wave surges on first RNA editing data in humans

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).

News

Head and neck cancer trials 'becoming less diverse'

Despite efforts in the US to increase the diversity of clinical trials, a study has found that in one form of cancer the trend seems to be going in the other direction.

News

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.

News

Pfizer sticks $1.5bn on Triana's molecular glue tech

Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 bi

News

Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

NIH study backs Bavarian Nordic mpox jab for adolescents

Wave surges on first RNA editing data in humans

Head and neck cancer trials 'becoming less diverse'

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Pfizer sticks $1.5bn on Triana's molecular glue tech

Transgene cervical cancer shot misses the mark in phase 2

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

News

Editor's Picks